MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
1.540
-0.020
-1.28%
Pre Market: 1.530 -0.01 -0.65% 09:16 05/13 EDT
OPEN
1.560
PREV CLOSE
1.560
HIGH
1.640
LOW
1.495
VOLUME
22.93K
TURNOVER
0
52 WEEK HIGH
1.850
52 WEEK LOW
0.7720
MARKET CAP
145.60M
P/E (TTM)
-3.0519
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLS last week (0505-0509)?
Weekly Report · 1d ago
Sellas Life Sciences Group Inc <SLS.OQ> expected to post a loss of 10 cents a share - Earnings Preview
Reuters · 4d ago
Weekly Report: what happened at SLS last week (0428-0502)?
Weekly Report · 05/05 09:58
Promising Preclinical Data and Strategic Developments Drive Buy Rating for SELLAS Life Sciences Group
TipRanks · 04/30 18:05
Sellas Life Sciences announces preclinical data of SLS009 in AML
TipRanks · 04/28 12:47
Sellas Life Sciences Presents Preclinical Efficacy Of SLS009 In TP53 Mutated AML Cells At AACR Conference
Benzinga · 04/28 12:47
Weekly Report: what happened at SLS last week (0421-0425)?
Weekly Report · 04/28 10:02
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
Barchart · 04/28 07:45
More
About SLS
More
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Recently
Symbol
Price
%Change
    EH
  • 19.22
  • +4.17%

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.